ADBE
47
-9
HIG
48
-6
UAL
70
-6
WFC
60
-3
NWS
56
-4
CSX
46
2
VRTX
54
-2
FLR
48
-4
C
58
-2
GOOG
83
-4
TAP
58
-3
NOV
40
-3
ICE
59
-3
DE
53
-3
BBY
42
-6
PNR
69
-3
AIZ
68
4
EFX
49
3
WU
32
2
BDX
60
6
ADBE
47
-9
HIG
48
-6
UAL
70
-6
WFC
60
-3
NWS
56
-4
CSX
46
2
VRTX
54
-2
FLR
48
-4
C
58
-2
GOOG
83
-4
TAP
58
-3
NOV
40
-3
ICE
59
-3
DE
53
-3
BBY
42
-6
PNR
69
-3
AIZ
68
4
EFX
49
3
WU
32
2
BDX
60
6
Financhill
Back

UroGen Pharma 10K Form

Sell
43

URGN
UroGen Pharma

Last Price:
11.36
Seasonality Move:
5.08%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2023-11-14 10Q URGN/UroGen Pharma Quarterly
2023-08-10 10Q URGN/UroGen Pharma Quarterly
2023-05-11 10Q URGN/UroGen Pharma Quarterly
2022-11-10 10Q URGN/UroGen Pharma Quarterly
2022-08-11 10Q URGN/UroGen Pharma Quarterly
2022-05-10 10Q URGN/UroGen Pharma Quarterly

Receive URGN News And Ratings

See the #1 stock for the next 7 days that we like better than URGN

URGN Financial Statistics

Sales & Book Value

Annual Sales: $82.71M
Cash Flow: $-27.76M
Price / Cash Flow: 0
Annual Sales: $0.60
Price / Book: 18.97

Profitability

EPS (TTM): -3.09000
Net Income (TTM): $-115.38M
Gross Margin: $73.35M
Return on Equity: 0%
Return on Assets: -49.89%

UroGen Pharma Earnings Forecast

Key UroGen Pharma Financial Ratios

  • The Gross Profit Margin over the past 9 years for URGN is 88.68%.
  • The Selling, General & Administrative Expenses for URGN have been equal to 112.77% of Gross Profit Margin.
  • The Research & Development expenses have been 55.15% of Revenue.
  • The Interest Expense is -14.39% of Operating Income.
  • The Net Earning history of URGN is -123.61% of Total Revenues.
  • Per Share Earnings over the last 9 years have been positive in 4 years.

UroGen Pharma Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: URGN
CUSIP: M96088
Website: urogen.com

Debt

Debt-to-Equity Ratio: 4.77
Current Ratio: 9
Quick Ratio: 8.31

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

URGN Technical Analysis vs Fundamental Analysis

Sell
43
UroGen Pharma (URGN) is a Sell

Is UroGen Pharma a Buy or a Sell?

  • UroGen Pharma stock is rated a Sell
    The current UroGen Pharma [URGN] share price is $11.47. The Score for URGN is 43, which is 14% below its historic median score of 50, and infers higher risk than normal.